Trospium Chloride Tablet, Film Coated
Product Images NDC 0574-0145

8 FDA label images from Padagis Us Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 0574-0145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical Structure (Image 01)
Chemical structure of trospium chloride, showing the molecular arrangement including a quaternary ammonium ion with chloride and associated bicyclic and aromatic groups.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A pharmacokinetic line graph showing plasma concentration (ng/mL) of a drug over time (hours post-dose) up to 48 hours. Data points with error bars illustrate plasma concentration peaking around 2-4 hours, then gradually decreasing to near baseline by 48 hours.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph comparing the mean (±SE) change over time in a study with two groups: placebo (N=256) and trospium chloride tablets (N=253). The x-axis represents weeks of treatment (1, 4, and 12), and the y-axis shows the mean change. Trospium chloride tablets show a greater decrease compared to placebo, with p-values indicated at various weeks (p=0.051 at week 1, p<0.001 at weeks 4 and 12). Error bars are displayed on the data points.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph depicting mean (±SE) change over weeks of treatment comparing Trospium Chloride Tablets (N=253) with placebo (N=256). The x-axis shows weeks 1, 4, and 12, and the y-axis measures mean change values, illustrating differences between treatment groups over time with associated p-values.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line graph comparing the mean change in a measured variable over weeks of treatment between placebo and Trospium Chloride tablets. The x-axis shows treatment weeks (1, 4, and 12), and the y-axis shows mean change with standard error bars. Trospium Chloride shows greater mean reduction than placebo throughout the treatment period.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph comparing mean change over weeks of treatment between Placebo and Trospium Chloride Tablets groups. The x-axis shows weeks of treatment (1, 4, 12) and the y-axis shows mean change values with standard error. Trospium Chloride tablets consistently show greater mean change than placebo, with significance levels noted at p<0.001.*
FDA Label Image

Label (Label Rev10 23)

Label (Label Rev10 23)
Label for Trospium Chloride Tablets, 20 mg film-coated oral tablets. The package contains 60 tablets and is labeled by Padagis US LLC. The label includes storage instructions to keep between 20° to 25°C, warnings to keep out of children's reach, and refers to the package insert for prescribing information. It also shows the product NDC 0574-0145-60 and includes barcodes and lot/expiration date area.*
FDA Label Image

Serialization Template (Serialization Template)

Serialization Template (Serialization Template)
A text panel containing placeholders for product identification information. It includes fields for serial number (S/N), lot number, and expiration date (Exp) of the product. The panel is formatted with bracketed prompts indicating where specific product details should be inserted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.